KRT18 and metabolic dysfunction-associated steatohepatitis: Although not all studies agree on a positive effect [70,71,72] (Table 3), a randomised placebo-controlled study with long-term intervention in patients with histologically proven NASH showed beneficial effects on both transaminase levels, disease activity assessed by circulating levels of cleaved cytokeratin 18 (CK-18) and insulin resistance [72].